MOTS-c Mechanism of Action
FIG. I · MECHANISM / AMPK TRANSMISSION
MOTS-c enters the folate-AICAR-AMPK axis, driving glucose uptake and fat oxidation via downstream gear-train effects in skeletal muscle and liver.
MOTS-c operates through the folate-AICAR-AMPK axis. The peptide is secreted from mitochondria into the cytoplasm, where it inhibits folate cycling and de novo purine biosynthesis. This inhibition causes AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide, an endogenous AMPK activator — to accumulate. Elevated AICAR activates AMPK, which then drives increased glucose uptake via GLUT4 translocation in skeletal muscle, enhanced beta-oxidation of fatty acids, and suppression of hepatic lipid accumulation.[1][17]
Under metabolic stress — glucose restriction, serum deprivation — MOTS-c translocates from the cytoplasm to the nucleus within 30 minutes, AMPK-dependently. In the nucleus it physically interacts with NRF2 and upregulates ARE-target genes NQO1 and HO-1, establishing MOTS-c as a direct retrograde mitochondria-to-nucleus signaling molecule.[4]
A 2024 study identified CK2alpha (casein kinase 2 alpha) as a direct molecular binding target. MOTS-c binds CK2alpha at approximately 1 nM affinity in skeletal muscle, activating it and preventing atrophy while enhancing glucose uptake. The same study showed MOTS-c suppresses CK2 in adipose tissue — a tissue-specific duality that accounts for some of the peptide's opposing metabolic effects across compartments.[12]
A separate 2024 study identified a non-metabolic role: MOTS-c facilitates translocation of the membrane-repair scaffold protein TRIM72 (MG53) to the sarcolemma after exercise. MOTS-c and TRIM72 co-localization at the plasma membrane attenuated exercise-induced membrane damage in a TRIM72-dependent manner.[15]
Additional pathways identified across the literature: TGF-beta/SMAD (bone metabolism), STAT3 inhibition (anti-atrophic signaling), mitochondrial biogenesis via TFAM and COX4 upregulation, and ERK-mediated adipose browning.[14][17]
MOTS-c Benefits: Evidence from the Literature
Published interventional literature reports measurable effects across several organ systems in preclinical models.
FINDING · I · METABOLISM
Metabolic Regulation — Lee 2015, Cell Metabolism
In diet-induced obese mice, MOTS-c at 15 mg/kg/day intraperitoneal reduced body weight gain, improved glucose tolerance, lowered fasting insulin, and decreased hepatic lipid accumulation via AMPK activation in skeletal muscle. MOTS-c also prevented age-dependent glucose intolerance in old mice.[1]
FINDING · II · ENDURANCE
Exercise Performance — Reynolds 2021, Nature Communications
Exogenous MOTS-c significantly improved treadmill running capacity and rotarod performance in young (2 months), middle-aged (12 months), and old (22 months) mice. Old mice treated with MOTS-c outperformed untreated middle-aged controls.[2]
FINDING · III · MUSCLE
Muscle Atrophy Prevention — Human Myotubes
At 10 µM in primary human myotubes, MOTS-c completely preserved myotube cross-sectional area and fusion index against glucocorticoid-induced atrophy. MOTS-c reduced MURF1 expression, enhanced Akt phosphorylation, and suppressed STAT3 activation.[13]
FINDING · IV · CARDIAC
Cardiac Protection — Zhong 2022 / Pham 2025
In a mouse heart-failure model (transverse aortic constriction), MOTS-c at 5 mg/kg/day subcutaneous for four weeks attenuated cardiac dysfunction, reduced fibrosis, lowered inflammatory markers, and activated AMPK in cardiac tissue.[10] A 2025 rat study confirmed MOTS-c restores mitochondrial respiration in the type-2-diabetic heart.[11]
FINDING · V · BONE
Bone Metabolism — Postmenopausal Models
MOTS-c promoted osteoblast collagen production via TGF-beta/SMAD signaling and inhibited osteoclastogenesis in postmenopausal mouse models.[20]
PRECLINICAL ONLY
All interventional benefit data are from rodent models
Human interventional data are absent. Available human data are cross-sectional or observational.
Metabolic Effects: Fat Reduction and Insulin Sensitivity
Lee et al. (Cell Metabolism, 2015) is the foundational metabolic study. MOTS-c at 15 mg/kg/day in diet-induced obese mice reduced adiposity, improved insulin sensitivity, and lowered liver fat via AMPK activation. Lower doses of 2.5 mg/kg were also tested and showed insulin-sensitizing effects.[1]
A 2019 metabolomics study confirmed the mechanism in obese mice: MOTS-c at 2.5 mg/kg twice daily for three days reduced plasma sphingolipid, monoacylglycerol, and dicarboxylate metabolites — pathways elevated in obesity and type 2 diabetes — while enhancing beta-oxidation.[5]
Human observational data are consistent: circulating MOTS-c is significantly lower in obese male children and adolescents versus healthy controls (465 vs 584 ng/mL, P<0.001), inversely correlated with BMI, waist circumference, fasting insulin, HOMA-IR, and HbA1c.[7] A separate cohort of 443 pediatric subjects confirmed reduced serum MOTS-c in obese children.[8]
MOTS-c and Exercise Performance
Reynolds et al. (Nature Communications, 2021) established MOTS-c as an exercise-induced peptide and a driver of age-dependent physical capacity. Three key findings:
- Exogenous MOTS-c at 5 mg/kg three times per week subcutaneous produced a twofold improvement in treadmill running distance in middle-aged and old mice versus controls.[2]
- Human stationary cycling induced an 11.9-fold increase in skeletal muscle MOTS-c expression and a 1.5–1.6-fold rise in circulating MOTS-c, returning to near-baseline within four hours post-exercise.[3]
- Late-life intermittent treatment (3×/week from approximately 24 months in mice) improved grip strength, stride length, and walking capacity, with a trend toward 6.4% extended median lifespan.[2]
A 2023 human observational study (n=20 physically active adults) found serum MOTS-c positively correlated with lower-body muscle force, average power, and muscle mass (countermovement jump), with no correlation with VO2 max — suggesting MOTS-c relates specifically to explosive/high-intensity muscular capacity rather than aerobic endurance.[16]
MOTS-c and Aging Biology
FIG. II · AGING / GOVERNOR MECHANISM
The governor's descending needle represents the 21% decline in circulating MOTS-c observed in 70–81-year-old humans versus 18–30-year-olds.
Circulating MOTS-c declines with age: plasma levels in 45–55-year-olds are 11% lower than in 18–30-year-olds; in 70–81-year-olds they are 21% lower.[6]
In parallel, skeletal muscle MOTS-c expression is approximately 1.5-fold higher in older versus younger men, suggesting compensatory tissue upregulation as systemic levels fall. Muscle MOTS-c expression positively correlated with slow-twitch fiber markers and with muscle quality in older men.[6]
Mechanistically, MOTS-c shares pathway overlap with longevity interventions: it activates NAD+ synthesis pathways and operates downstream of AMPK, which is also activated by caloric restriction and metformin. Rodent studies show cognitive and physical decline attenuated in aged mouse models.[19]
MOTS-c and Longevity
Intermittent MOTS-c treatment (5 mg/kg 3×/week subcutaneous) extended healthy lifespan in aged male mice in the Reynolds et al. 2021 study — a trend toward 6.4% extended median lifespan alongside improved physical capacity in old mice. This is animal data; the mechanism relevant to longevity involves improved metabolic homeostasis and reduced age-related physical decline.[2]
Human longevity data are observational. The 2021 K14Q variant analysis (27,527 subjects) found no longevity association in 736 Japanese centenarians, qualifying earlier longevity speculation from smaller cohort studies.[9]
Is MOTS-c an Exercise Mimetic?
Mouse studies show exogenous MOTS-c increases physical endurance and recapitulates some transcriptional signatures of exercise — particularly AMPK-driven metabolic reprogramming in skeletal muscle.[2] Exercise also induces endogenous MOTS-c production in human skeletal muscle, establishing a bidirectional relationship.[3]
Whether exogenous MOTS-c fully recapitulates the exercise-training effect in humans is not established. No controlled human exercise trial has been published. The exercise-mimetic characterization in the literature is based on rodent phenotype data.
MOTS-c Before and After: Findings from Animal and Human Studies
Pre/post study designs in the MOTS-c literature report measurable changes across several outcomes in rodent models:
- Fat mass: reduced in diet-induced obese mice after MOTS-c treatment vs untreated controls[1]
- Fasting insulin: reduced in obese mice[1]
- Glucose tolerance: improved in diet-induced obese and aged mice[1]
- Treadmill distance: twofold increase in middle-aged and old mice after MOTS-c vs vehicle[2]
- Grip strength and stride length: improved in late-life-treated mice[2]
- Cardiac function markers: improved in pressure-overload heart failure model mice[10]
- Mitochondrial respiration: restored in type-2-diabetic rat hearts[11]
NO HUMAN DATA
Human pre/post interventional data are absent. Available human data are cross-sectional or observational.
MOTS-c vs Humanin and SHLP2: Mitochondrial-Derived Peptide Comparisons
FIG. III · DISAMBIGUATION / MDP COMPARISON PLATE
MOTS-c, humanin, and SHLP2 — three peptide classes from the same mitochondrial engine, each with distinct gears for distinct biological functions.
All three are mitochondrial-derived peptides — but the similarities stop at the genome origin.[18]
| Property | MOTS-c | Humanin | SHLP2 |
|---|---|---|---|
| Gene region | MT-RNR1 (12S) | MT-RNR2 (16S) | MT-RNR2 (16S) |
| Size | 16 amino acids | 21 amino acids | 24–38 amino acids |
| Primary role | Metabolic regulation, AMPK activation | Cytoprotection, neuroprotection | Neuroprotection, OXPHOS restoration |
| Primary tissues | Skeletal muscle, liver, adipose | Brain, retina, gonads | Retina, brain, pancreas |
| WADA status | Prohibited S4.4.1 | Not listed (2025) | Not listed (2025) |
Genomic location: MOTS-c is encoded by the 12S rRNA region of mtDNA (MT-RNR1). Humanin and SHLP1–6 are all encoded by the 16S rRNA region (MT-RNR2). This difference in genomic context is fundamental: MT-RNR1 and MT-RNR2 are transcribed and regulated separately.
Receptor targets: MOTS-c acts primarily intracellularly via AMPK/AICAR and nuclear NRF2; humanin binds cell-surface receptors including FPRL-1, FPRL-2, and CNTFR alpha. This makes humanin's pharmacology substantially different from MOTS-c's.
Human Clinical Trial Status
NO HUMAN TRIAL DATA
No Completed Phase 2 or Phase 3 Trials Published
No completed Phase 2 or Phase 3 clinical trials for the native MOTS-c 16-amino-acid sequence have been published as of 2025.
Available human data:
- Exercise-induced endogenous MOTS-c in healthy young males (Reynolds et al. 2021)[3]
- Observational studies of circulating MOTS-c across age groups and obesity cohorts[6][7][8]
- Serum MOTS-c correlations with muscle force in physically active adults (n=20)[16]
- Genetic association study: K14Q mtDNA variant in 27,527 subjects[9]
CB-4211, a MOTS-c analog developed for obesity, entered early human trials, but peer-reviewed Phase 2 results have not been published.
MOTS-c and Weight Loss Research
Rodent data show fat-mass reduction via enhanced fatty acid oxidation and AMPK-mediated glucose uptake. Lee et al. 2015 demonstrated significant adiposity reduction in obese mice.[1] The metabolomics study confirmed reduced obesity-related plasma metabolite signatures.[5]
No human weight-loss randomized controlled trial has been published. Weight reduction in humans is not an approved or validated application for MOTS-c.
What Are the Main MOTS-c Peptide Benefits?
Published literature reports: improved insulin sensitivity and reduced adiposity (Lee 2015, Cell Metabolism)[1]; enhanced mitochondrial biogenesis and metabolic flexibility in rodent models[17]; increased physical endurance in young, middle-aged, and old mice (Reynolds 2021, Nature Communications)[2]; potential lifespan improvement in aged male mice (Reynolds 2021 — trend, not significant)[2]; and associations between higher endogenous MOTS-c and lower obesity-related metabolic markers in human observational studies.[7][8]
All interventional benefit data are from rodent models. Human interventional data are absent.